Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact firstname.lastname@example.org
SOURCE Research and Markets
DUBLIN, Feb. 28, 2018 /PRNewswire/ --
The "RSV Diagnostics Market by Product (Kits and Assays, Instruments), Method (Rapid Antigen Detection Test, Molecular Diagnostic), End User (Hospitals & Clinics, Clinical Laboratories, Homecare) - Global Forecast to 2022" report has been added to ResearchAndMarkets.com's offering.
The global RSV diagnostics market is expected to reach USD 929.2 Million by 2022 from USD 574.3 Million in 2017, at a CAGR of 10.1%.
Market growth is primarily driven by the rising burden of RSV infections, growing demand for PoC molecular diagnostic tests for the diagnosis of RSV infections, and increasing approval of RSV diagnostic kits and assays.
The global RSV diagnostics market is segmented based on product, method, end user, and region. By product, the global market is segmented into kits and assays, instruments, and other products. The kits and assays segment is estimated to account for the largest share of the global market in 2017. Factors driving the growth of this segment include the growing patient base of RSV disease and increasing demand for kits and assays for RSV diagnosis.
The RSV diagnostics market by method is segmented into rapid antigen detection tests, molecular diagnostics, and other methods. The molecular diagnostics segment is estimated to account for the largest share of the global market in 2017. Growing demand for molecular diagnostic tests for the diagnosis of RSV infections, and increasing approval of RSV diagnostic kits and assays are the major factors driving the growth of this segment.
The RSV diagnostics market by end user is segmented into hospitals and clinics, clinical laboratories and home care. The hospitals and clinics segment is estimated to account for the largest share of the global market. Increasing burden of RSV disease among children, increasing demand for RSV diagnosis in hospitals and clinics and increasing adoption of PoC molecular diagnostic devices in hospitals and clinics for RSV diagnosis are the major factors driving the growth of this segment.
The global RSV diagnostics market is dominated by North America, followed by Europe. North America will continue to dominate the global market in the forecast period. However, Asia Pacific is expected to witness the highest CAGR. Factors such as the increasing burden of infectious disease such as RSV and focus of major players in emerging Asia Pacific countries are driving the growth of the RSV diagnostics market in this region. While development of a RSV vaccine in the forecast period is expected to be a major challenge for the global market.
Major industry players launched innovative products to maintain and improve their position in the RSV diagnostics market. bioMerieux (France), Becton Dickinson (US), Abbott (US), Roche (Switzerland), Danaher (US), Luminex (US), BioCartis (Belgium), Hologic (US), and Fast Track Diagnostics (Luxembourg) have been identified as key players in this market. These companies have broad product portfolios with comprehensive features and have also launched innovative products. These leaders also have products for all end users in this market, strong geographical presence, and a focus on continuous product innovation.
For more information about this report visit https://www.researchandmarkets.com/research/hvjsv6/rsv_diagnostics?w=5
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
©2017 PR Newswire. All Rights Reserved.